Immunotherapy drugs are becoming increasingly popular choices for treating certain cancers. A recent study compares both the overall survival (OS) and progression-free survival (PFS) of both PD-1 and PD-L1 inhibitors.

The following article analyzed data from 19 different studies with over 11,000 patients receiving either PD-1 inhibitors such as nivolumab (Opdivo) and pembrolizumab (Keytruda), or PD-L1 inhibitors such as avelumab (Bavencio) or atezolizumab (Tecentriq). What they found was clear differences in both OS and PFS with PD-1 inhibitors being clearly superior. Both immunotherapy drugs (PD-1 and PD-L1) had similar side effects.

If  you have read Cancer: Improving Your Odds you know there are natural ways to improve your odds (response) to these checkpoint inhibitor type drugs. See Chapter 2 of the book for more information. You can also find out more about the book on the information page.